- Home
- LU vs ARWR Comparison
LU vs ARWR Comparison
Compare LU & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- ARWR
- Stock Information
- Founded
- LU 2005
- ARWR 2003
- Country
- LU China
- ARWR United States
- Employees
- LU N/A
- ARWR N/A
- Industry
- LU Finance: Consumer Services
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- ARWR Health Care
- Exchange
- LU Nasdaq
- ARWR Nasdaq
- Market Cap
- LU 2.5B
- ARWR 2.5B
- IPO Year
- LU 2020
- ARWR 1993
- Fundamental
- Price
- LU $3.02
- ARWR $29.72
- Analyst Decision
- LU Hold
- ARWR Strong Buy
- Analyst Count
- LU 1
- ARWR 8
- Target Price
- LU $3.20
- ARWR $47.75
- AVG Volume (30 Days)
- LU 1.9M
- ARWR 3.0M
- Earning Date
- LU 10-20-2025
- ARWR 08-07-2025
- Dividend Yield
- LU N/A
- ARWR N/A
- EPS Growth
- LU N/A
- ARWR N/A
- EPS
- LU N/A
- ARWR N/A
- Revenue
- LU $4,671,260,668.00
- ARWR $572,976,000.00
- Revenue This Year
- LU N/A
- ARWR $22,306.37
- Revenue Next Year
- LU N/A
- ARWR N/A
- P/E Ratio
- LU N/A
- ARWR N/A
- Revenue Growth
- LU N/A
- ARWR 2816.20
- 52 Week Low
- LU $2.13
- ARWR $9.57
- 52 Week High
- LU $4.15
- ARWR $31.13
- Technical
- Relative Strength Index (RSI)
- LU 53.66
- ARWR 76.98
- Support Level
- LU $2.93
- ARWR $27.10
- Resistance Level
- LU $3.27
- ARWR $29.34
- Average True Range (ATR)
- LU 0.12
- ARWR 1.47
- MACD
- LU -0.00
- ARWR 0.47
- Stochastic Oscillator
- LU 34.62
- ARWR 86.89
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.